Endothelial function of human gastroepiploic artery. Implications for its use as a bypass graft.
The human gastroepiploic artery has been used as a coronary artery bypass conduit in a limited number of clinical studies. It has been postulated that the capacity of the endothelium to release vasoactive substances may contribute to differing patency rates observed in established bypass grafts. We have now examined endothelial function in the human gastroepiploic artery. Endothelium-dependent relaxations to substance P were observed. A maximum relaxation of 83.25% +/- 8.2% (mean +/- standard error) was attenuated to 48.5% +/- 16.4% in the presence of L-NG-monomethyl-arginine, a specific inhibitor of endogenous nitric oxide synthesis. Removal of the endothelium abolished the relaxations. With a specific radioimmunoassay, concomitant changes in levels of cyclic guanosine 3',5'-monophosphate, the second messenger that elicits smooth muscle relaxation after release of the endothelium-derived relaxing factor, were measured. It was found that the gastroepiploic artery had significantly higher resting and stimulated levels of cyclic guanosine 3',5'-monophosphate than either the internal mammary artery or the saphenous vein. In the presence of the cyclooxygenase inhibitor indomethacin, and indomethacin plus L-NG-monomethylanginine, the maximum relaxation was decreased to 70% +/- 9.5% and 59% +/- 10.8%, respectively. Our data demonstrate that endothelium-derived relaxing factor and prostacyclin may exhibit synergy in the control of vascular tone in this vessel. It is concluded that the endothelium of the gastroepiploic artery has a strong capacity to secrete vasodilators and inhibitors of platelet activity. This could have important influence on long-term patency.
O'Neil
G S
GS
National Heart and Lung Institute, Harefield Hospital, Middlesex, England.
Chester
A H
AH
Allen
S P
SP
Luu
T N
TN
Tadjkarimi
S
S
Ridley
P
P
Khagani
A
A
Musumeci
F
F
Yacoub
M H
MH
D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001026:Coronary Artery Bypass / Q000379:methods*; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D005996:Nitroglycerin / Q000494:pharmacology; D013270:Stomach / Q000098:blood supply*; D013373:Substance P / Q000494:pharmacology*; D014654:Vascular Patency / Q000502:physiology*; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D019323:omega-N-Methylarginine
D019323:omega-N-Methylarginine; D013373:Substance P; D001120:Arginine; D005996:Nitroglycerin; D006152:Cyclic GMP; D007213:Indomethacin